The role of 18F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging

Hellenic Journal of Nuclear Medicine

Volumn 14, Issue 2, 2011, Pages

  Mittal, Bhagwant Rai ^a   Manohar, Kuruva ^a   Kashyap, Raghava ^a   Bhattacharya, Anish ^a   Singh, Baljinder ^a   Singh, Gurpreet ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Distant metastases; Locally advanced breast carcinoma; Pet CT 18F FDG

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; ARTICLE; AXILLARY LYMPH NODE; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THORAX RADIOGRAPHY; ULTRASOUND; WHOLE BODY IMAGING;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79961145227     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo, PA. Cancer Statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Whitman GJ, Strom EA. Workup and Staging of Locally Advanced Breast Cancer. Semin Radiat Oncol 2009; 19(4): 211-21.
3. Al-Husaini H, Amir E, Fitzgerald B et al. Prevalence of Overt Metastases in Locally Advanced Breast Cancer Clinical Oncology 2008; 20: 340-4.
4. Franceschini G, Terribile D, Magno S et al. Update in the treatment of locally advanced breast cancer: A multidisciplinary approach. Eur RevMed Pharmacol Sci 2007; 11: 283-9. (Pubitemid 350213809)
5. Cristofanilli M, Valero V, Buzdar AU et al. Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease. Cancer 2007; 110: 1436-44. (Pubitemid 47463056)
6. Yang WT, Le-Petross HT, Macapinlac H et al. Inflammatory breast cancer: PET/ CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat 2008; 109: 417-26. (Pubitemid 351692058)
7. Fueger BJ, Weber WA, Quon A et al. Performance of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol 2005; 7: 369-76. (Pubitemid 44193414)
8. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007; 27: S215-S29.
9. Tatsumi M, Cohade C, Mourtzikos KA et al. Initial experience with FDG PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33: 254-62.
10. Kumar R, Chauhan A, Zhuang H et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006; 98: 267-74. (Pubitemid 44195596)
11. Wahl RL, Siegel BA, Coleman RE, Gatsonis CG, PET Study Group. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the Staging Breast Cancer with PET Study Group. J Clin Oncol 2004; 22: 277-85. (Pubitemid 41095092)
12. Gil-Rendo A, Zornoza G. Garcüa-Velloso MJ et al. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006; 93: 707-12. (Pubitemid 43886022)
13. Kumar R, Zhuang H, Schnall M et al. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 2006; 27: 231-6. (Pubitemid 44391810)
14. Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 2005; 35: 84-99. (Pubitemid 40568742)
15. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90: 105-12. (Pubitemid 40568893)
16. Radan L, Ben-Haim S, Bar-Shalom R et al. The role of FDG-PET/ CT in suspected recurrence of breast cancer. Cancer 2006; 107: 2545-51. (Pubitemid 44845606)
17. Avril N, Rose CA, Schelling M et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 3495-502.
18. 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med 2009; 50: 231-8.
19. 18F-2-fluoro-2- deoxy-D-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004; 22: 1253-9. (Pubitemid 41079839)
20. Lim HS, Yoon W, Chung TW et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007; 27: S197-S213.
21. Hodgson NC, Gulenchyn KY. Is there a role for positron emission tomography in breast cancer staging? J Clin Oncol 2008; 26: 712-20. (Pubitemid 351264383)
22. Veronesi U, De Cicco C, Galimberti VE et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007; 18: 473-8. (Pubitemid 46359625)
23. Bernstein V, Jones A, Mankoff DA, Davis NI. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission (FDGPET) in medial hemisphere breast cancer [abstract]. J Nucl Med 2000; 41: 289P.
24. 18F-FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9. (Pubitemid 28481635)